Abstract:Background: Human urate transporter 1 (hURAT1) is the most pivotal therapeutic target for treating hyperuricemia. However, the molecular interactions between uric acid and URAT1 are still unknown due to lack of structural details. Methods: In the present study, several methods (homology modeling, sequence alignment, docking, and mutagenesis) were used to explain the atomistic mechanisms of uric acid transport of hURAT1. Results: Residues W357-F365 in the TMD7 and P484-R487 in the TMD11 present in the hURAT1 have unique roles in both binding to the uric acid and causing subsequent structural changes. These residues, located in the transport tunnel, were found to be related to the structural changes, as demonstrated by the reduced Vmax values and an unaltered expression of protein level. In addition, W357, G361, T363, F365, and R487 residues may confer high affinity for binding to uric acid. An outward-open homology model of hURAT1 revealed a crucial role for these two domains in the conformational changes of hURAT1. F241 and H245 in TMD5, and R477 and R487 in TMD11 may confer high affinity for uric acid, and as the docking analysis suggests, they may also enhance the affinity for the inhibitors. R477 relation to the structural changes was demonstrated by the Vmax values of the mutants and the contribution of positive charge to the uric acid selectivity. Conclusions: W357-F365 in TMD7, P484-R487 in TMD11, and residues F241, H245, and R477 were found to be critical for the translocation and recognition of uric acid.This article has not yet been cited by other publications.

[Phylogenetic studies on some Japanese amphibia by mean of immunoelectrophoresis. I. Relationships of some frogs and newt to toad (author's transl)].

Mechanisms of urate transport and uricosuric drugs inhibition in human URAT1

Molecular mechanisms of uric acid transport by the native human URAT1 and its inhibition by anti-gout drugs

Two distinct mechanisms for ornithine decarboxylase regulation by polyamines in rat hepatoma cells

Molecular basis of the urate transporter URAT1 inhibition by gout drugs

Structural Insights into the Mechanisms of Urea Permeation and Distinct Inhibition Modes of Urea Transporters

Structural Insights into the Atomistic Mechanisms of Uric Acid Recognition and Translocation of Human Urate Anion Transporter 1

Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present)

Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout

Urate Transporter URAT1 Inhibitors: a Patent Review (2012 - 2015)

A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications

Structural basis for urate recognition and apigenin inhibition of human GLUT9

Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities

A GROUP PARTICIPATION-DEMONSTRATION METHOD OF INTRODUCING PATIENTS TO GROUP PARTICIPATION-DEMONSTRATION METHOD OF INTRODUCING PATIENTS TO GROUP PSYCHOTHERAPY.

A System for Discovering Novel Uricosurics Targeting Urate Transporter 1 Based on In Vitro and In Vivo Modeling

Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout

Mutation in Transmembrane Domain 8 of Human Urate Transporter 1 Disrupts Uric Acid Recognition and Transport

Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability

Structure and Mechanism of the Uracil Transporter Uraa

Dimeric Structure of the Uracil:Proton Symporter UraA Provides Mechanistic Insights into the SLC4/23/26 Transporters

LECTURE NOTES FOR 416: JORDAN CANONICAL FORM